Compare Stocks: LFWD, HSAQ, CNXU, and RNXT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CNXU Conexeu Sciences	$2.22 -4.7%	$3.68	$2.01 ▼ $18.79	$65.72M	N/A	381,111 shs	207,055 shs
HSAQ Health Sciences Acquisitions Co. 2	$5.70 +0.4%	$5.74	$9.41 ▼ $13.80	$63.91M	0.09	205,918 shs	785,151 shs
LFWD Lifeward	$5.89 -0.9%	$6.48	$4.14 ▼ $9.61	$16.82M	0.55	21,718 shs	6,575 shs
RNXT RenovoRx	$1.18	$1.52	$0.70 ▼ $2.59	$56.94M	1.12	444,888 shs	251,131 shs

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CNXU Conexeu Sciences	-4.72%	-6.72%	-42.93%	-69.63%	+221,999,900.00%
HSAQ Health Sciences Acquisitions Co. 2	+0.35%	+0.18%	-4.20%	+29.55%	+49.61%
LFWD Lifeward	-0.93%	+0.94%	-9.32%	-24.06%	-11.84%
RNXT RenovoRx	0.00%	-8.53%	-7.81%	+5.36%	+18.45%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CNXU Conexeu Sciences	$2.22 -4.7%	$3.68	$2.01 ▼ $18.79	$65.72M	N/A	381,111 shs	207,055 shs
HSAQ Health Sciences Acquisitions Co. 2	$5.70 +0.4%	$5.74	$9.41 ▼ $13.80	$63.91M	0.09	205,918 shs	785,151 shs
LFWD Lifeward	$5.89 -0.9%	$6.48	$4.14 ▼ $9.61	$16.82M	0.55	21,718 shs	6,575 shs
RNXT RenovoRx	$1.18	$1.52	$0.70 ▼ $2.59	$56.94M	1.12	444,888 shs	251,131 shs

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CNXU Conexeu Sciences	-4.72%	-6.72%	-42.93%	-69.63%	+221,999,900.00%
HSAQ Health Sciences Acquisitions Co. 2	+0.35%	+0.18%	-4.20%	+29.55%	+49.61%
LFWD Lifeward	-0.93%	+0.94%	-9.32%	-24.06%	-11.84%
RNXT RenovoRx	0.00%	-8.53%	-7.81%	+5.36%	+18.45%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CNXU Conexeu Sciences	2.00	Hold	$20.00	800.90% Upside
HSAQ Health Sciences Acquisitions Co. 2	0.00	N/A	N/A	N/A
LFWD Lifeward	2.25	Hold	$10.00	69.92% Upside
RNXT RenovoRx	2.75	Moderate Buy	$8.50	620.34% Upside

Current Analyst Ratings Breakdown

Latest LFWD, HSAQ, CNXU, and RNXT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
11/2/2026	CNXU Conexeu Sciences	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E-) ➝ Sell (E)
10/9/2026	LFWD Lifeward	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
9/24/2026	LFWD Lifeward	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
9/2/2026	LFWD Lifeward	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
9/2/2026	RNXT RenovoRx	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
8/21/2026	LFWD Lifeward	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
8/21/2026	LFWD Lifeward	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$10.00
8/18/2026	LFWD Lifeward	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
8/18/2026	RNXT RenovoRx	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
8/17/2026	CNXU Conexeu Sciences	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Sell (E-)

(Data available from 11/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CNXU Conexeu Sciences	N/A	N/A	N/A	N/A	N/A	N/A
HSAQ Health Sciences Acquisitions Co. 2	N/A	N/A	N/A	N/A	($0.62) per share	N/A
LFWD Lifeward	$22.03M	0.76	N/A	N/A	$5.52 per share	1.07
RNXT RenovoRx	$1.12M	50.83	N/A	N/A	$0.19 per share	6.21

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CNXU Conexeu Sciences	-$3.92M	-$0.40	N/A	N/A	N/A	N/A	-200.20%	-177.26%	N/A
HSAQ Health Sciences Acquisitions Co. 2	-$380K	N/A	N/A	N/A	N/A	N/A	N/A	-2.38%	N/A
LFWD Lifeward	-$19.91M	-$16.82	N/A	N/A	N/A	-141.28%	-235.86%	-81.72%	11/13/2026 (Estimated)
RNXT RenovoRx	-$11.17M	-$0.31	N/A	N/A	N/A	-469.02%	-133.49%	-101.50%	N/A

Latest LFWD, HSAQ, CNXU, and RNXT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/13/2026	Q3 2026	LFWD Lifeward	-$0.7850	N/A	N/A	N/A	$7.24 million	N/A
11/5/2026	Q3 2026	RNXT RenovoRx	-$0.06	-$0.07	-$0.01	-$0.08	$1.06 million	$1.07 million
9/14/2026	Q3 2026	CNXU Conexeu Sciences	-$0.10	-$0.29	-$0.19	-$0.29	N/A	N/A
8/15/2026	Q2 2026	LFWD Lifeward	-$1.39	-$1.46	-$0.07	-$4.12	$6.53 million	$6.62 million
8/12/2026	Q2 2026	RNXT RenovoRx	-$0.0725	-$0.05	+$0.0225	-$0.06	$0.70 million	$0.91 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CNXU Conexeu Sciences	N/A	N/A	N/A	N/A	N/A
HSAQ Health Sciences Acquisitions Co. 2	N/A	N/A	N/A	N/A	N/A
LFWD Lifeward	N/A	N/A	N/A	N/A	N/A
RNXT RenovoRx	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CNXU Conexeu Sciences	N/A	5.31	5.31
HSAQ Health Sciences Acquisitions Co. 2	N/A	0.17	0.61
LFWD Lifeward	0.70	2.33	1.77
RNXT RenovoRx	N/A	5.65	5.53

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CNXU Conexeu Sciences	N/A
HSAQ Health Sciences Acquisitions Co. 2	89.71%
LFWD Lifeward	26.76%
RNXT RenovoRx	3.10%

Insider Ownership

Company	Insider Ownership
CNXU Conexeu Sciences	N/A
HSAQ Health Sciences Acquisitions Co. 2	21.90%
LFWD Lifeward	1.10%
RNXT RenovoRx	9.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CNXU Conexeu Sciences	4	28.21 million	N/A	N/A
HSAQ Health Sciences Acquisitions Co. 2	4	11.21 million	8.76 million	Not Optionable
LFWD Lifeward	81	2.83 million	2.80 million	No Data
RNXT RenovoRx	17	48.25 million	40.89 million	Not Optionable

LFWD, HSAQ, CNXU, and RNXT Headlines

Recent News About These Companies

Brokers Offer Predictions for RenovoRx FY2026 Earnings

November 10 at 6:11 AM | marketbeat.com

HC Wainwright Estimates RenovoRx's Q4 Earnings (NASDAQ:RNXT)

November 9 at 1:59 AM | americanbankingnews.com

RenovoRx (NASDAQ:RNXT) Rating Lowered to "Sell" at Wall Street Zen

November 9 at 1:07 AM | americanbankingnews.com

RenovoRx Q3 Earnings Call Highlights

November 6, 2026 | marketbeat.com

RenovoRx (RNXT) Q3 2026 Earnings Call Transcript

November 6, 2026 | finance.yahoo.com

RenovoRx Reports Record Third Quarter 2026 Revenue Exceeding $1 Million

November 6, 2026 | markets.businessinsider.com

RenovoRx (NASDAQ:RNXT) Issues Quarterly Earnings Results

November 5, 2026 | marketbeat.com

RenovoRx, Inc. (RNXT) Reports Q3 Loss, Tops Revenue Estimates

November 5, 2026 | zacks.com

What To Expect From RenovoRx Inc (RNXT) Q3 2026 Earnings

November 4, 2026 | finance.yahoo.com

RenovoRx (NASDAQ:RNXT) & Beta Bionics (NASDAQ:BBNX) Financial Analysis

November 2, 2026 | americanbankingnews.com

RenovoRx (NASDAQ:RNXT) Stock Moved Up to "Hold" by Wall Street Zen

November 1, 2026 | americanbankingnews.com

RenovoRx (NASDAQ:RNXT) Stock Rating Upgraded by Wall Street Zen

November 1, 2026 | marketbeat.com

RenovoRx (RNXT) Expected to Post Earnings on Thursday

October 29, 2026 | marketbeat.com

RenovoRx to Participate at the Canaccord Genuity MedTech Diagnostics and Digital Health & Services Forum

October 28, 2026 | globenewswire.com

RenovoRx (NASDAQ:RNXT) Stock Gets Downgrade from Wall Street Zen

October 24, 2026 | marketbeat.com

RenovoRx (NASDAQ:RNXT) Stock Price Up 3.3% - Should You Buy?

October 23, 2026 | marketbeat.com

RenovoRx to Report Third Quarter 2026 Financial Results and Host Conference Call on November 5

October 22, 2026 | quiverquant.comQ

RenovoRx to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026

October 22, 2026 | globenewswire.com

RenovoRx Advances TAMP into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial

October 8, 2026 | marketscreener.comM

RenovoRx Enrolls First Patient In UVM-Sponsored Pancreatic Cancer PRISM-TAMP Trial

October 8, 2026 | rttnews.com

RenovoRx Advances TAMP™ into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial

October 7, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LFWD, HSAQ, CNXU, and RNXT Company Descriptions

Conexeu Sciences NASDAQ:CNXU

$2.22 -0.11 (-4.72%)

Closing price 11/10/2026 04:00 PM Eastern

Extended Trading

$2.22 0.00 (0.00%)

As of 11/10/2026 07:30 PM Eastern

Conexeu is a company focused on building a new class of collagen-based regenerative tissue products. The Company was incorporated on November 2, 2022 under the Business Corporations Act (British Columbia) and was continued out of British Columbia and domesticated into the State of Nevada under the laws of the State of Nevada on April 10, 2025. --- Conexeu is an early-stage medical device company formed to acquire and commercialize intellectual property ("IP") developed over more than a decade at the University of British Columbia (the "University") and the BC Professional Firefighters Burn and Wound Healing Laboratory. In November 2023, the Company entered into a patent assignment agreement with the University pursuant to which the Company acquired an assignment of the University's right, title, and interest in the applicable patents and patent applications related to the underlying technology. The Company's only device candidate is the CXU™ scaffold device candidate, which is in preclinical development and has not been approved or cleared for marketing in any jurisdiction. The Company is conducting preclinical research and preparing for regulatory engagement to evaluate potential use in wound care and other medical applications. Any potential benefits to patients, providers, or healthcare systems have not been established and will require further study and regulatory review. CXU™ is a temperature-responsive, collagen-based extracellular matrix ("ECM") formulation designed to transition from a liquid to a gel-like scaffold following topical application or injection, typically within approximately ten minutes (the "10 Minute Tissue™" concept). The device IP is protected by issued and pending patents and is being evaluated in preclinical studies for its ability to provide an ECM-like environment associated with cellular infiltration, vascularization, and organized tissue remodeling in non-clinical models. We intend to seek U.S. Food and Drug Administration ("FDA") clearance in the United States for the CXU™ scaffold device candidate through the 510(k) premarket notification process as a Class II medical device; however, the FDA has not yet determined the appropriate classification or regulatory pathway for our device candidate, may require additional data or a different pathway, and there can be no assurance that we will obtain clearance or that the device candidate will become commercially available. Our principal executive offices are located in Reno, Nevada.

Health Sciences Acquisitions Co. 2 NASDAQ:HSAQ

$5.70 +0.02 (+0.35%)

As of 11/9/2026

Health Sciences Acquisitions Corporation 2 does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or related business combination with one or more businesses in the biopharma and medical technology sectors in North America or Europe. Health Sciences Acquisitions Corporation 2 was incorporated in 2020 and is based in New York, New York.

Lifeward NASDAQ:LFWD

$5.88 -0.06 (-0.93%)

Closing price 11/10/2026 03:59 PM Eastern

Extended Trading

$5.81 -0.08 (-1.27%)

As of 11/10/2026 04:10 PM Eastern

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke. The company markets and sells its products directly to institutions and individuals, as well as through third-party distributors. The company was formerly known as Argo Medical Technologies Ltd. ReWalk Robotics Ltd. was incorporated in 2001 and is headquartered in Yokneam Illit, Israel.

RenovoRx NASDAQ:RNXT

$1.18 0.00 (0.00%)

Closing price 11/10/2026 04:00 PM Eastern

Extended Trading

$1.14 -0.04 (-3.31%)

As of 11/10/2026 07:55 PM Eastern

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LFWD, HSAQ, CNXU, and RNXT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LFWD, HSAQ, CNXU, and RNXT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LFWD, HSAQ, CNXU, and RNXT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LFWD, HSAQ, CNXU, and RNXT Company Descriptions

Conexeu Sciences NASDAQ:CNXU

Health Sciences Acquisitions Co. 2 NASDAQ:HSAQ

Lifeward NASDAQ:LFWD

RenovoRx NASDAQ:RNXT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LFWD, HSAQ, CNXU, and RNXT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LFWD, HSAQ, CNXU, and RNXT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LFWD, HSAQ, CNXU, and RNXT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LFWD, HSAQ, CNXU, and RNXT Company Descriptions

Conexeu Sciences NASDAQ:CNXU

Health Sciences Acquisitions Co. 2 NASDAQ:HSAQ

Lifeward NASDAQ:LFWD

RenovoRx NASDAQ:RNXT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools